Lisata Therapeutics Inc LSTA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if LSTA is a good fit for your portfolio.
News
-
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma
-
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events
-
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
-
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
-
Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
-
Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ
-
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
-
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time
Trading Information
- Previous Close Price
- $2.78
- Day Range
- $2.73–2.86
- 52-Week Range
- $1.95–4.53
- Bid/Ask
- $1.20 / $3.09
- Market Cap
- $23.67 Mil
- Volume/Avg
- 1,130 / 13,626
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 25
- Website
- https://www.lisata.com
Valuation
|
Metric
|
LSTA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.48 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
LSTA
Financial Strength
|
Metric
|
LSTA
|
|---|---|
Quick Ratio | 7.67 |
Current Ratio | 8.18 |
Interest Coverage | — |
Quick Ratio
LSTA
Profitability
|
Metric
|
LSTA
|
|---|---|
Return on Assets (Normalized) | −30.21% |
Return on Equity (Normalized) | −33.15% |
Return on Invested Capital (Normalized) | −33.17% |
Return on Assets
LSTA
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Frffxsfd | Mpnk | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rmbrrwj | Yltsxm | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Znwqdjn | Fsqcvd | $98.1 Bil | |
MRNA
| Moderna Inc | Rmjcfmst | Zff | $39.1 Bil | |
ARGX
| argenx SE ADR | Lhjttcln | Tpsv | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Sfrtbflh | Ydhjv | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gmygljts | Rrfndj | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jzbwvxsc | Cfblsr | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hbzkfcchr | Nvfjs | $12.5 Bil | |
INCY
| Incyte Corp | Sklhybsdb | Gpjntdj | $11.9 Bil |